Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
JWP-Led Holdings Firm Launched for Nichi-Iko, Kyowa, and Teva Takeda
A new holding company has been established to oversee Nichi-Iko Pharmaceutical, Kyowa Pharmaceutical Industry, and Teva Takeda Pharma - three firms backed by Japanese private equity firm J-Will Partners (JWP) and wholesaler Medipal Holdings. The company, And Pharma, was formally…
To read the full story
Related Article
- And Pharma Group Subsidiaries Team Up for First Joint Promotion
October 23, 2025
- Mochida and Itochu to Each Take 20% Stake in And Pharma
September 24, 2025
- And Pharma Chief Pledges Growth Strategy as New Generics Holding Firm Takes Shape
September 5, 2025
- Teva Takeda Renamed as T’s Pharma
September 2, 2025
- Nippon Chemiphar Signs On to Meiji-Daito Consortium as Talks Accelerate
July 22, 2025
- Nichi-Iko to Start Production Collaboration with Kyowa in FY2025: President
January 29, 2025
- Generic Industry Shakeup Advances as Teva Takeda Joins JWP-Medipal Group
December 9, 2024
- Japan Employees Shaken by Teva’s Divestment Plan, Soft Landing Wanted on Supply Front
June 4, 2024
- Teva to Let Go of Japan Generic Business in 2025 but Denies Full Exit
May 15, 2024
- Kyowa Pharma Joins Medipal-JWP JV, Now Sister Firm to Nichi-Iko
March 6, 2024
BUSINESS
- TS Alfresa-Backed Drone Council Inks Pact with Hiroshima
October 19, 2026
- Santen to Seek Bankruptcy for Chinese Subsidiary
October 19, 2026
- Toho Invests in Keio Offshoot AdipoSeeds
October 19, 2026
- Amgen, JASSO Team Up on Obesity Research and Care
October 19, 2026
- Sanwa Kagaku to Resume Kumamoto Production on October 19
October 19, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…